CN106794185A - Rucaparib的高剂量强度片剂 - Google Patents

Rucaparib的高剂量强度片剂 Download PDF

Info

Publication number
CN106794185A
CN106794185A CN201580042815.9A CN201580042815A CN106794185A CN 106794185 A CN106794185 A CN 106794185A CN 201580042815 A CN201580042815 A CN 201580042815A CN 106794185 A CN106794185 A CN 106794185A
Authority
CN
China
Prior art keywords
tablet
active pharmaceutical
pharmaceutical ingredient
methyl
rucaparib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580042815.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·埃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clovis Oncology Inc
Original Assignee
Clovis Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clovis Oncology Inc filed Critical Clovis Oncology Inc
Priority to CN202110458329.2A priority Critical patent/CN113209033A/zh
Publication of CN106794185A publication Critical patent/CN106794185A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580042815.9A 2014-08-22 2015-08-17 Rucaparib的高剂量强度片剂 Pending CN106794185A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110458329.2A CN113209033A (zh) 2014-08-22 2015-08-17 Rucaparib的高剂量强度片剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110458329.2A Division CN113209033A (zh) 2014-08-22 2015-08-17 Rucaparib的高剂量强度片剂

Publications (1)

Publication Number Publication Date
CN106794185A true CN106794185A (zh) 2017-05-31

Family

ID=55347324

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580042815.9A Pending CN106794185A (zh) 2014-08-22 2015-08-17 Rucaparib的高剂量强度片剂
CN202110458329.2A Pending CN113209033A (zh) 2014-08-22 2015-08-17 Rucaparib的高剂量强度片剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110458329.2A Pending CN113209033A (zh) 2014-08-22 2015-08-17 Rucaparib的高剂量强度片剂

Country Status (23)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR20170043597A (enExample)
CN (2) CN106794185A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PL (1) PL3182975T3 (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108853030A (zh) * 2018-09-26 2018-11-23 李敏 一种治疗恶性肿瘤的药物制剂及其制备方法
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
HK1232218A1 (zh) 2014-02-05 2018-01-05 Merck Sharp & Dohme Llc Cgrp-活性化合物的片剂制剂
DK3182975T3 (da) * 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
ES2985767T3 (es) 2017-01-24 2024-11-07 Assia Chem Ind Ltd Formas en estado sólido de rucaparib y de sales de rucaparib
EP3600314A1 (en) 2017-03-27 2020-02-05 Tesaro, Inc. Niraparib compositions
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
KR20230002487A (ko) 2020-04-28 2023-01-05 리젠 파마슈티컬스 아게 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물
HRP20251324T1 (hr) 2020-07-14 2025-12-05 Assia Chemical Industries Ltd. Oblici soli rukapariba u krutom stanju
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
BR112023020615A2 (pt) 2021-04-08 2023-12-19 Incozen Therapeutics Pvt Ltd Inibidores de poli(adp-ribose) polimerase
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
US11738029B2 (en) * 2021-11-10 2023-08-29 Crititech, Inc. Rucaparib particles and uses thereof
US20250223295A1 (en) 2022-01-11 2025-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102884066A (zh) * 2010-02-12 2013-01-16 辉瑞公司 8-氟-2-{4-[(甲氨基)甲基]苯基}-1,3,4,5-四氢-6H-氮杂*并[5,4,3-cd]吲哚-6-酮的盐和多晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
JP2008513436A (ja) 2004-09-22 2008-05-01 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態
PL1794163T3 (pl) 2004-09-22 2010-06-30 Pfizer Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
CA2720744A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
PT2833973T (pt) 2012-04-05 2017-12-21 Vertex Pharma Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
DK3182975T3 (da) 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102884066A (zh) * 2010-02-12 2013-01-16 辉瑞公司 8-氟-2-{4-[(甲氨基)甲基]苯基}-1,3,4,5-四氢-6H-氮杂*并[5,4,3-cd]吲哚-6-酮的盐和多晶型物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOYCE F. LIU等: "PARP inhibitors in ovarian cancer: Current status and future promise", 《GYNECOLOGIC ONCOLOGY》 *
陆彬: "《药剂学》", 31 January 2003, 中国医药科技出版社 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
TWI843707B (zh) * 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030A (zh) * 2018-09-26 2018-11-23 李敏 一种治疗恶性肿瘤的药物制剂及其制备方法
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途

Also Published As

Publication number Publication date
CA2955495C (en) 2023-09-19
MX2017001540A (es) 2017-05-11
JP6574477B2 (ja) 2019-09-11
EP3182975B1 (en) 2025-10-01
SI3182975T1 (sl) 2025-12-31
ES3048688T3 (en) 2025-12-11
RU2017109139A (ru) 2018-09-24
RS67356B1 (sr) 2025-11-28
US20180200260A1 (en) 2018-07-19
EP3182975A4 (en) 2018-04-18
KR102803917B1 (ko) 2025-05-07
NZ728392A (en) 2023-06-30
AU2015305696B2 (en) 2019-08-29
RU2017109139A3 (enExample) 2019-03-06
PL3182975T3 (pl) 2026-02-23
SG11201700265VA (en) 2017-02-27
LT3182975T (lt) 2025-11-25
JP2020002149A (ja) 2020-01-09
IL249946A0 (en) 2017-03-30
WO2016028689A1 (en) 2016-02-25
US10130636B2 (en) 2018-11-20
CA2955495A1 (en) 2016-02-25
AU2019272064B2 (en) 2021-11-18
KR20170043597A (ko) 2017-04-21
MX367260B (es) 2019-08-12
BR112017000865A2 (pt) 2017-12-05
JP2021038242A (ja) 2021-03-11
PT3182975T (pt) 2025-10-28
US20190099430A1 (en) 2019-04-04
AU2019272064A1 (en) 2019-12-19
FI3182975T3 (fi) 2025-11-13
CN113209033A (zh) 2021-08-06
JP7127101B2 (ja) 2022-08-29
EP3182975A1 (en) 2017-06-28
HRP20251484T1 (hr) 2026-01-02
AU2015305696A1 (en) 2017-02-02
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
US20160051561A1 (en) 2016-02-25
JP6797980B2 (ja) 2020-12-09
RU2705156C2 (ru) 2019-11-05
US9987285B2 (en) 2018-06-05
KR20230097211A (ko) 2023-06-30
JP2017525712A (ja) 2017-09-07

Similar Documents

Publication Publication Date Title
JP7127101B2 (ja) ルカパリブの高投与力価錠剤
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
KR101406767B1 (ko) 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
EP3949967A1 (en) Solid pharmaceutical composition comprising tlr7 agonist
US20060222703A1 (en) Pharmaceutical composition and preparation method thereof
US20180344648A1 (en) Clobazam tablet formulation and process for its preparation
CN108420798A (zh) 一种抗凝剂的速释药物制剂及其制备方法
EP3784218A1 (en) Tablet compositions comprising abiraterone acetate
JP2025524357A (ja) 多数の顆粒
WO2016139681A2 (en) Pharmaceutical composition of tizanidine and process for preparing the same
HK1232807A1 (en) High dosage strength tablets of rucaparib
HK1232807B (en) High dosage strength tablets of rucaparib
HK40068797A (en) Solid pharmaceutical composition comprising tlr7 agonist
HK1149481A (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170531

RJ01 Rejection of invention patent application after publication